Related Experiment Video
Updated: Jun 12, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Rosuvastatin-induced thrombocytopenia
Ioannis Vrettos1, Sotiris Papageorgiou, Christina Economopoulou
1Second Department of Internal Medicine, Propaedeutic, University of Athens, Medical School, Attikon University General Hospital, Haidari, Athens, Greece.
Southern Medical Journal
|June 10, 2010
Summary
Rosuvastatin is generally well-tolerated but can rarely cause severe thrombocytopenia (low platelet count). This case study highlights a patient who developed this rare adverse effect while on rosuvastatin treatment.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Rosuvastatin is a widely prescribed statin for managing hyperlipidemia.
- Common side effects include gastrointestinal issues, myalgia, and hepatitis.
- Severe thrombocytopenia is a rare but serious adverse effect of statin therapy.
Observation:
- A case of a 65-year-old patient experiencing severe thrombocytopenia is presented.
- The patient developed this condition while undergoing treatment with rosuvastatin.
Findings:
- This report details a rare instance of severe thrombocytopenia linked to rosuvastatin use.
- A literature review on statin-induced thrombocytopenia is included.
Implications:
- Clinicians should be aware of the potential for severe thrombocytopenia in patients taking rosuvastatin.
- Monitoring platelet counts may be considered in patients developing unexplained bleeding or bruising during statin therapy.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.